Berylson Capital Partners, LLC Exelixis, Inc. Transaction History
Berylson Capital Partners, LLC
- $40.7 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
460Shares Held
240MCall Options Held
2.04MPut Options Held
1.29M-
Black Rock Inc. New York, NY33.5MShares$888 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$786 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$718 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$402 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$334 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $8.53B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...